diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5404diaendo-5404Research ArticleСтатьиArticlesКомментарии к консенсусному алгоритму Американской Диабетической Ассоциациии Европейской Ассоциации по изучению сахарного диабета: ?Медикаментозная коррекция гипергликемии при сахарном диабете 2 типа?Comments on the Consensus statement of the American Diabetes Association and the European Association for the Studyof Diabetes on the medical management of hyperglycemia in type 2 diabetesДедовИван ИвановичDedovIvan Ivanovich-ШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna-ВикуловаОльга КонстантиновнаVikulovaOlga Konstantinovnaolga-vikuliva-1973@yandex.ruФГУ Эндокринологический научный центр Росмедтехнологий, МоскваEndocrinology Research Centre, Moscow200915062009122№2 (2009)7782Copyright © Дедов И.И., Шестакова М.В., Викулова О.К., 20092009Дедов И.И., Шестакова М.В., Викулова О.К.Dedov I.I., Shestakova M.V., Vikulova O.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5404

В декабре 2008 года опубликована обновленная версия ал- горитма медикаментозной терапии сахарного диабета 2 типа (СД2) Американской Диабетической Ассоциа- ции (ADA) и Европейской Ассоциации по изучению сахарного диабета (EASD) , в которой обсуждаются основные аспекты лечения данного заболевания. Мы хотели бы подчеркнуть чрезвычайную важность консенсуса, обусловленную целым рядом причин.

сахарный диабетконсенсусгипергликемиямедикаментозная коррекцияdiabetes mellitusconsensushyperglycemiamedicamentous correctionReferencesNathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the study of diabetes. Diabetes care 2008; 31:1-11.Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the study of diabetes. Diabetes care 2008; 31:1-11.American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes care 2008; 31(suppl 1): S12-S54.American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes care 2008; 31(suppl 1): S12-S54.Guideline for management of postmeal glucose.// International Diabetes Federation, 2007. Available at: http://www.idf.org.Guideline for management of postmeal glucose.// International Diabetes Federation, 2007. Available at: http://www.idf.org.The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compered with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compered with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.Duckworth W, Abraira C, Mortiz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; DOI: 10.1056/NEJMoa0808431.Duckworth W, Abraira C, Mortiz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; DOI: 10.1056/NEJMoa0808431.The ADVANCE Collaborative Group: intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.The ADVANCE Collaborative Group: intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.Holman RR, Paul SJ, Bethel MA, et al. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; DOI: 10.1056/NEJMoa0806470. Available at: http://theheart.orgHolman RR, Paul SJ, Bethel MA, et al. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; DOI: 10.1056/NEJMoa0806470. Available at: http://theheart.orgKahn SE, Haffner SM, Heise MA, et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.Kahn SE, Haffner SM, Heise MA, et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.Schwarts AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54.Schwarts AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54.Home PD, Pocock SJ, Beck-Nielsen et al. Rosiglitazone evaluated for cardiovascular outcomes - An Interim Analysis. N Engl J Med 2007; 357: 28-38.Home PD, Pocock SJ, Beck-Nielsen et al. Rosiglitazone evaluated for cardiovascular outcomes - An Interim Analysis. N Engl J Med 2007; 357: 28-38.Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 2007; 30:2248-2254.Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 2007; 30:2248-2254.Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomised trials. JAMA 2007; 298:1180-1188.Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomised trials. JAMA 2007; 298:1180-1188.Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005;366:1279-1289.Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005;366:1279-1289.Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356: 2457-2471.Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356: 2457-2471.Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298:1189-1195.Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298:1189-1195.The DREAM (Diabetes Reduction Asessment with ramipril and rosiglitasone Medication) Trial Investigators. Effect of rosiglitasone on the frequency of diabetes in patientswith impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. //Lancet 2006; 368:1096-1105.The DREAM (Diabetes Reduction Asessment with ramipril and rosiglitasone Medication) Trial Investigators. Effect of rosiglitasone on the frequency of diabetes in patientswith impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. //Lancet 2006; 368:1096-1105.

The authors declare that there are no conflicts of interest present.